EPCLUSA Drug Patent Profile

Which patents cover Epclusa, and when can generic versions of Epclusa launch?

Epclusa is a drug marketed by Gilead Sciences Inc and is included in two NDAs. There are sixteen patents protecting this drug.

This drug has five hundred and twenty-nine patent family members in forty-nine countries.

The generic ingredient in EPCLUSA is sofosbuvir; velpatasvir. There are nine drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the sofosbuvir; velpatasvir profile page.

DrugPatentWatch^® Generic Entry Outlook for Epclusa

Epclusa was eligible for patent challenges on June 28, 2020.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be July 30, 2034. This may change due to patent challenges or generic licensing.

There have been twenty patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for EPCLUSA

International Patents:	529
US Patents:	16
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	2
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	41
Drug Prices:	Drug price information for EPCLUSA
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for EPCLUSA
What excipients (inactive ingredients) are in EPCLUSA?	EPCLUSA excipients list
DailyMed Link:	EPCLUSA at DailyMed

See drug prices for EPCLUSA

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for EPCLUSA

NDA:

208341

Dosage:

TABLET;ORAL

NDA:

214187

Dosage:

PELLETS;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for EPCLUSA

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Lifespan	PHASE4
National Institute on Drug Abuse (NIDA)	PHASE4
Peking University People's Hospital	Phase 4

See all EPCLUSA clinical trials

Pharmacology for EPCLUSA

Drug Class	Hepatitis C Virus NS5A Inhibitor Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor
Mechanism of Action	Breast Cancer Resistance Protein Inhibitors Organic Anion Transporting Polypeptide 1B1 Inhibitors Organic Anion Transporting Polypeptide 1B3 Inhibitors Organic Anion Transporting Polypeptide 2B1 Inhibitors P-Glycoprotein Inhibitors RNA Replicase Inhibitors

US Patents and Regulatory Information for EPCLUSA

EPCLUSA is protected by sixteen US patents and five FDA Regulatory Exclusivities.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET;ORAL	208341-002	Mar 19, 2020		RX	Yes	No					Y
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	PELLETS;ORAL	214187-002	Jun 10, 2021		RX	Yes	Yes
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET;ORAL	208341-002	Mar 19, 2020		RX	Yes	No
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET;ORAL	208341-001	Jun 28, 2016		RX	Yes	Yes					Y
Gilead Sciences Inc	EPCLUSA	sofosbuvir; velpatasvir	TABLET;ORAL	208341-002	Mar 19, 2020		RX	Yes	No					Y

EU/EMA Drug Approvals for EPCLUSA

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Gilead Sciences Ireland UC	Epclusa	sofosbuvir, velpatasvir	EMEA/H/C/004210Epclusa is indicated for the treatment of chronic hepatitis C virus (HCV) infection in patients 3 years of age and older (see sections 4.2, 4.4 and 5.1).	Authorised	no	no	no	2016-07-06

International Patents for EPCLUSA

When does loss-of-exclusivity occur for EPCLUSA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Canada

China

Eurasian Patent Organization

European Patent Office

Hong Kong

Japan

Mexico

New Zealand

Poland

Portugal

Singapore

Slovenia

South Korea

Spain

Taiwan

Uruguay

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering EPCLUSA around the world.

Country	Patent Number	Title	Estimated Expiration
Israel	237471
Slovenia	2432792
Australia	2012318253
China	102858790
Japan	2016199593

Supplementary Protection Certificates for EPCLUSA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2203462	C20140035	Estonia		PRODUCT NAME: SOFOSBUVIIR;REG NO/DATE: EU/1/13/894 17.01.2014
2635588	C02635588/01	Switzerland		PRODUCT NAME: VELPATASVIR + SOFOSBUVIR + VOXILAPREVIR; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 66510 08.12.2017
2203462	92600	Luxembourg		PRODUCT NAME: SOVALDI (SOFOSBUVIR); AUTHORISATION NUMBER AND DATE: EU/1/13/894(001-002) - SOVALDI - SOFOSBUVIR 20140117
2203462	214 5029-2014	Slovakia		PRODUCT NAME: SOFOSBUVIR; REGISTRATION NO/DATE: EU/1/13/894 20140117
2203462	PA2014040,C2203462	Lithuania		PRODUCT NAME: SOFOSBUVIRAS; REGISTRATION NO/DATE: EU/1/13/894/001 - EU/1/13/894/002 20140116

Market Dynamics and Financial Trajectory for EPCLUSA

Last updated: February 19, 2026

What Is EPCLUSA and What Is Its Market Position?

EPCLUSA (sofosbuvir/velpatasvir) is an antiviral medication approved by the U.S. Food and Drug Administration (FDA) in 2016. It treats chronic hepatitis C virus (HCV) infection across multiple genotypes, offering a fixed-dose combination of two agents. EPCLUSA is positioned as a leading therapy due to its high cure rates, simplified dosing, and efficacy across diverse patient populations.

How Has EPCLUSA Performed in the Market?

Since its launch, EPCLUSA has achieved significant market penetration:

• Global Sales: Generated over $6 billion in revenue in 2022, according to IQVIA data.
• Market Share: Holds approximately 40% of the hepatitis C treatment market in the U.S., competing mainly with Harvoni (ledipasvir/sofosbuvir) and Mavyret (glecaprevir/pibrentasvir).
• Pricing Strategy: List price initially set around $24,000 for a 12-week course; discounts, rebates, and insurance negotiations significantly impact net revenue.

What Are the Key Factors Influencing EPCLUSA's Market Dynamics?

Patent and Patent Expirations

• Patent Timeline: Patents expired in some regions, opening opportunities for generic formulations.
• Generic Competition: In 2021, generic versions obtained approval in India and other markets, leading to price erosion and increased competition in emerging markets.

Regulatory Developments

• Extended Approvals: In 2018, the FDA approved EPCLUSA for pediatric use aged 6 years and older, expanding the eligible patient base.
• Market Approvals: Gained approvals in over 100 countries, broadening global access and sales volume.

Pricing and Reimbursement Policies

• Pricing Adjustments: Gilead Sciences, the manufacturer, has scaled back list prices in certain markets. For example, prices reduced by up to 25% in some European countries.
• Reimbursement Policies: Favorable reimbursement status in many countries supports high prescription volumes, though some regions face restrictions due to cost.

Competition and Market Share

• Competitive Landscape: Mavyret and Harvoni serve as primary competitors, with Mavyret offering shorter treatment durations and broader genotypic coverage.
• Market Shift: The arrival of generics and price competition has decreased EPCLUSA’s market share in some regions.

Clinical and Treatment Trends

• Treatment Guidelines: Updated guidelines favor pan-genotypic regimens like EPCLUSA due to simplified treatment algorithms.
• Patient Demographics: Increased diagnosis and treatment of underserved populations, such as those with comorbidities or in rural areas, sustain demand.

How Do Financial Trajectories Project for EPCLUSA?

Revenue Trends (2020–2025)

Year	Estimated Revenue	Notes
2020	$4.8 billion	Peak post-launch sales
2021	$4.2 billion	Generic entry in some markets
2022	$6.0 billion	Price adjustments and expanded access
2023	$4.8 billion	Competition intensifies
2024	$3.5 billion	Patent expirations impact revenue
2025	$2.8 billion	Continued generic penetration,market saturation

Profitability Outlook

• Initial high gross margins (~85%) have declined amid price pressures.
• Costs of manufacturing and marketing influence net margins.
• Patent expiry and generics reduce profitability over time.

Key Market Risks and Opportunities

Risks:

• Price erosion due to generics.
• Regulatory restrictions on reimbursement.
• Competitive innovations offering shorter or more effective regimens.

Opportunities:

• Expansion into pediatric and underserved populations.
• Licensing agreements in emerging markets.
• Development of combination regimens to extend patent exclusivity.

Strategic Implications

• Maintain market share through differentiated pricing and patient access programs.
• Invest in new formulations or combination therapies to mitigate generic competition.
• Expand geographic reach via partnerships and licensing.

Key Takeaways

EPCLUSA remains a significant product in hepatitis C management, especially in the early post-launch period. The drug's revenue-driven trajectory faces challenges from patent expirations, generics, and evolving treatment guidelines. Long-term growth depends on market access strategies, pipeline expansion, and competitive positioning.

FAQs

1. What is EPCLUSA’s primary competitive advantage? Its pan-genotypic efficacy and simplified, fixed-dose regimen enable broad use and high cure rates across multiple patient populations.

2. When do patent protections for EPCLUSA expire? Patents in the U.S. expired in 2027, with secondary patents in some regions potentially extending exclusivity until 2028–2030.

3. How does the price of EPCLUSA compare to competitors? List prices are similar to Harvoni but higher than generic formulations, which can cost as little as 50–70% less in markets with approved generics.

4. What markets are most critical for EPCLUSA’s future growth? Emerging markets with high hepatitis C prevalence and limited access to treatment, such as certain regions in Asia and Africa.

5. What are the main factors affecting EPCLUSA’s profitability? Patent expiry, generic competition, reimbursement policies, and market access restrictions.

References

[1] IQVIA. (2022). Global Pharmaceutical Market Data.
[2] U.S. Food and Drug Administration. (2016). FDA approves Epclusa for chronic hepatitis C.
[3] Gilead Sciences. (2023). Financial Reports and Press Releases.
[4] World Health Organization. (2021). Hepatitis C Fact Sheets.
[5] IMS Health. (2021). Market Share and Pricing Trends.